Firefly and NeuroSigma partner to expand FDA-cleared pediatric ADHD treatment
Firefly Neuroscience and NeuroSigma have formed a strategic partnership to expand awareness and access to the Monarch eTNS System, a non-drug treatment for certain pediatric ADHD patients. The collaboration combines NeuroSigma’s FDA-cleared device with Firefly’s clinician network and brain-function assessment tools to identify eligible children and support at-home use where appropriate.
What is changing
The Monarch eTNS System, a non-drug electrical nerve stimulation device, is being more widely offered as a treatment option for children aged 7 to 12 who have ADHD and are deemed eligible by a clinician. The deal aims to make clinicians more aware of the option and to connect families with a device that is used at home under medical guidance.
Key facts you should know
- Monarch eTNS is FDA-cleared as a non-drug treatment for pediatric ADHD, not a replacement for all therapies.
- The partnership centers on Firefly’s nationwide clinician network and objective brain-function assessments, which can help identify suitable candidates.
- The treatment is intended for children in a specific age range (7-12) and requires clinician oversight.
- Firefly provides tools for measuring brain function and research into biomarkers related to ADHD, potentially informing when to use the device.
Who is affected
The primary audience includes children aged 7 to 12 with ADHD and their families, along with pediatric clinicians who treat ADHD. The arrangement may affect patients who prefer non-drug options or who have not responded fully to medications, as well as healthcare providers who assess eligibility and oversee at-home use.
Practical next steps
- Families should discuss this option with their child’s pediatrician or ADHD specialist to determine eligibility.
- Clinicians within Firefly’s network may offer assessments and guidance on using Monarch at home, including any required training.
- Understand insurance coverage and out-of-pocket costs, since device programs and reimbursements vary by payer.
- Review safety and usage instructions for the Monarch eTNS System with a clinician before starting treatment.
Limits and questions
Monarch eTNS is one non-drug option among multiple evidence-based approaches for ADHD. The collaboration does not imply universal suitability or guarantee improvement for all patients. Key questions for families include: how to monitor effectiveness, potential side effects, duration of treatment, and integration with other therapies such as behavioral therapy or school supports.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.